The Shanghai Stock Exchange issued a regulatory warning to East Asia Pharmaceutical and relevant responsible persons.

Gelonghui, October 22 | The Shanghai Stock Exchange issued a decision to issue regulatory warnings to Zhejiang East Asia Pharmaceutical Co., Ltd. and relevant responsible persons. According to the findings in the ‘Decision on Ordering Rectification Measures for Zhejiang East Asia Pharmaceutical Co., Ltd.’ ((2025) No. 224) issued by the Zhejiang Securities Regulatory Bureau, the use of some of the company’s raised funds was inconsistent with the purposes disclosed in the prospectus for its initial public offering. The company failed to promptly fulfill the required review procedures, and the related information disclosure regarding the deposit and actual use of the raised funds was inaccurate. These actions violated relevant regulations. Regarding responsible individuals, Jia Feilong, the then Secretary of the Board of Directors of the company and the person specifically responsible for information disclosure affairs, failed to…